We previously reported the identification of HRPAP20 (hormone-regulated proliferation-associated protein 20), a novel hormone-regulated, proliferation-associated protein.
Introduction
Breast cancer is the second leading cause of death in women in Western countries (Dumitrescu and Cotarla, 2005) . Its morbidity and mortality are frequently the result of invasive disease, rather than caused by primary tumors themselves (Weigelt et al., 2004; Mariani, 2005) . Approximately one-third of human breast cancers initially develop as estrogen receptor positive (ER þ ), hormone-responsive tumors. However, with time, these may proceed to a more aggressive phenotype characterized by hormone independency, resistance to chemotherapy, and frequently, development of widespread, often lethal, metastases (Arafah et al., 1986; Leonessa et al., 1992) . The acquisition of a malignant phenotype by mammary epithelial cells involves disruption of coordinated intercellular communication and intracellular signaling, commonly accompanied with dysregulated gene expression and enhanced genomic instability (Williams and Smith, 1993; Strobl et al., 1995; Glinsky et al., 1997; Ellis, 2003; Subramaniam and Isaacs, 2005) . Therefore, increasing our understanding of the mechanisms that underlie malignant progression is critical for development of new therapeutic approaches to diagnose and treat breast cancer.
HRPAP20 (hormone-regulated proliferation-associated protein 20; accession no. NM_198783) was initially cloned in the rat Nb2 T lymphoma cell line (Karp et al., 2004) . Sequence analysis of its complementary DNA (cDNA) identified a single open-reading frame that encoded a novel 20.2 kDa protein. Motif analysis of the HRPAP20 amino-acid sequence revealed a putative calmodulin (CaM)-binding motif and several potential kinase recognition sequences. Results from experiments conducted in Nb2 cells and in the ER þ human breast adenocarcinoma cell line, MCF-7, revealed that HRPAP20 was indeed a phosphoprotein, the expression of which, was increased by prolactin (PRL), and inhibited by growth arrest. In transfection experiments, constitutive HRPAP20 expression increased proliferation and survival in the absence of PRL or serum, suggesting that it may function in growth and apoptosis regulation.
Based upon these observations linking HRPAP20 expression to phenotypic changes commonly associated with malignant progression, for example, enhanced growth and survival, we investigated whether HRPAP20 also affected the invasive capacity of tumor cells. We report that HRPAP20 increased the invasiveness of breast cancer cells through a mechanism coupled to a protein-protein interaction with CaM and increased matrix metalloproteinase-9 (MMP-9) secretion.
Results

HRPAP20 expression in human breast cancer cell lines and tumors
We previously showed that elevated HRPAP20 expression in transfection experiments provided a growth advantage in breast cancer cells (Karp et al., 2004) . Nevertheless, it was important to evaluate its endogenous expression in malignant breast cell lines and patient samples. HRPAP20 levels were determined in ER þ and weakly invasive MCF-7, and in ERÀ and malignant MDA-MB-231 and MDA-MB-435 cells. As shown in Figure 1 , HRPAP20 mRNA and protein were detectable in each cell line (panels a and b, respectively). In MDA-MB-231 and MDA-MB-435 cells, its endogenous level was significantly elevated compared to the less aggressive MCF-7 cell line, suggesting that HRPAP20 expression may be increased in invasive breast cancer cells.
To investigate whether HRPAP20 was also elevated in clinical breast cancer specimens, its expression was evaluated in human breast tumors, non-transformed surrounding tissue, and in healthy mammary tissue (obtained from reduction mammoplasty). As shown in Figure 1c , breast tumors from patients 44-84 years of age (n ¼ 7) exhibited a range in HRPAP20 mRNA expression. Nevertheless, the mean HRPAP20 level in the tumors was significantly elevated compared to control specimens (20-50 years of age; n ¼ 9). Importantly, HRPAP20 levels in each of the breast tumors, for which paired adjacent 'normal' tissue was available (n ¼ 5), were consistently elevated compared to their normal tissue counterparts. These results are consistent with the observations made in the cell lines and suggest that elevated HRPAP20 may be a common feature in breast cancer.
HRPAP20 increases breast cancer cell invasion
As elevated HRPAP20 was observed in malignant breast cancer cells, we assessed its effect on invasion in vitro. Toward this end, MCF-7 and MDA-MB-231 cells, each stably expressing elevated HRPAP20, were evaluated for their capacity to invade a Matrigel barrier in transwell chambers (Albini et al., 1987; Repesh, 1989; Paquette et al., 2005) . Despite the weak invasive capacity inherent in the MCF-7 line, elevated HRPAP20 mRNA (B20-fold) significantly increased its invasiveness (Po0.01) compared to cells transfected with the empty vector (Figure 2a) . Notably, further increasing HRPAP20 in MDA-MB-231 transfectants (Figure 2b ) increased invasion by threefold (Po0.01) above the already high level observed in this cell line. These observations suggest that elevated HRPAP20 increased the invasive capacity of tumor cells.
To further investigate the relationship between HRPAP20 and invasion, experiments were conducted in which it was knocked down using small interfering RNA (siRNA). With this approach, HRPAP20 mRNA expression in MCF-7 transfectants was reduced by >80%, 48 h subsequent to siRNA introduction (Figure 3a) . In these cells, reduced HRPAP20 was coupled to a significant (Po0.01) inhibition of invasion; the level in cells transfected with control siRNA did not significantly differ from that observed in control cultures (Figure 3b ). These results indicate that augmented invasiveness observed in the MCF-7 transfectants was HRPAP20 increases breast cancer invasion CM Karp et al reversed by knocking down HRPAP20 mRNA. As MCF-7/HRPAP20 cells express HRPAP20 derived from two sources, transfected and endogenous, additional experiments were conducted using wild-type MDA-MB-231 cells to determine whether knockdown of endogenous HRPAP20 would affect invasion. HRPAP20 siRNA reduced mRNA ( Figure 3c ) and protein expression by B70-80% (Figure 3c , inset) in these cells. Again, knockdown of HRPAP20 resulted in significant (Po0.01) inhibition of the invasive capacity of this cell line (Figure 3d ). Taken together, these results suggest that elevated HRPAP20 facilitated invasion in each of the breast cancer cell lines.
HRPAP20 increases MMP-9 secretion
The role of extracellular matrix (ECM)-degrading enzymes, including MMPs has been intensely investigated as an underlying mechanism in tumor extravasation and invasion (Murphy et al., 1989; Schmitt et al., 1990; Haupt et al., 2006) . Whereas several MMPs have been implicated in malignant progression (Bartsch et al., 2003; Mendes et al., 2005) , MMP-9 is correlated with poor patient survival in hormone-responsive breast tumors (Pellikainen et al., 2004; Rahko et al., 2004) . In addition, it has been suggested that the presence of immunoreactive MMP-9 in serum or urine from patients with metastatic breast cancer may represent a prognostic factor in advanced disease (La Rocca et al., 2004; Li et al., 2004; Di Carlo et al., 2005; Fernandez et al., 2005; Talvensaari-Mattila and Turpeenniemi-Hujanen, 2005) . Therefore, experiments were conducted to determine whether HRPAP20 affected secretion/activation of MMP-9. As illustrated in Figure 4a and b, conditioned 
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CM Karp et al medium from MCF-7/HRPAP20 cells contained significantly (Po0.05) increased MMP-9 gelatinolytic activity compared to empty vector-transfected controls. Moreover, analysis of MMP-9 activity in conditioned medium obtained from wild-type MDA-MB-231 cells revealed significantly (Po0.01) decreased MMP-9 secretion from cells in which HRPAP20 expression was knocked down compared to control cultures (Figure 4c and d). These observations suggest that HRPAP20 increased invasion, in part, by augmenting MMP-9 secretion.
HRPAP20 and CaM regulate MMP-9
Analysis of the amino-acid sequence of HRPAP20 using an algorithm to predict functional motifs indicated the presence of a putative CaM-binding motif in the region encompassing amino acids 54-74 (Figure 5a ). This region contains hydrophobic and basic residues at positions analogous to those in other well-characterized CaM-binding proteins (Figure 5b ; Bagchi et al., 1992; Fitzsimons et al., 1992) . Computer-assisted helical wheel analysis predicted the formation of an amphipathic a-helix with segregated hydrophobic and basic
Figure 4 HRPAP20 increases MMP-9 secretion. Conditioned medium from 1 Â 10 4 (empty vector or HRPAP20-transfected) MCF-7 cells was subjected to SDS-PAGE under non-denaturing conditions using gels containing 0.1% gelatin as a substrate. The gels were washed with a regenerating buffer followed by incubation in a developing buffer for 15 h at 371C. Protease activity was measured by densitometry following Coomassie staining of the gel. Enzymatically active MMP-9 served as a positive control. HRPAP20 increases breast cancer invasion CM Karp et al subdomains similar to other CaM-binding proteins (James et al., 1995; Figure 5c ). This conformation is thought to facilitate the interaction of the domain with the binding pocket of Ca 2 þ /CaM (Crivici and Ikura, 1995; Rhoads and Friedberg, 1997; Hoeflich and Ikura, 2002 ). An in vitro CaM pull-down assay was conducted in the presence and absence of Ca 2 þ , utilizing recombinant HRPAP20-GST to assess whether it formed a complex with CaM ( Figure 5d ). As shown, HRPAP20-GST bound to CaM-Sepharose in a Ca 2 þ -dependent manner. Minimal CaM binding of HRPAP20-GST was detected in the absence of the cation and no GST-only binding was observed. HRPAP20-GST, eluted from CaM-Sepharose, was identified by immunoblot analysis using a-GST and a-HRPAP20. These results indicate that HRPAP20 can complex with CaM in a purified system in vitro.
Co-immunoprecipitation/immunoblotting experiments were conducted to determine whether an HRPAP20-CaM complex could be identified in MCF-7 cells stably transfected with cDNAs encoding wild-type HRPAP20, an HRPAP20 variant harboring a K-A substitution in the CaM-binding domain (HRPAP20K73A, Figure 5c ), or the empty vector. As shown in Figure 6a , CaM coimmunoprecipitated in MCF-7/HRPAP20 cells using HRPAP20 antisera suggesting that a protein:protein complex between HRPAP20 and CaM was present. In contrast, significantly reduced CaM binding was observed in cells transfected with HRPAP20K73A containing the CaM-binding site amino-acid substitution compared to wild-type transfectants (Figure 6a and d) . The membranes from Figure 6a were subsequently stripped and reprobed with a-HRPAP20 to confirm HRPAP20 immunoprecipitation in each of the samples (Figure 6b ). Equal concentrations of lysate protein from each of the transfectants were immunoblotted using aCaM as a control (Figure 6c) . To assess whether an interaction between HRPAP20 and CaM was required for the increased invasiveness observed in cells expressing the elevated protein, the invasive capacity in vitro of the MCF-7 transfectants was assessed. As shown in Figure 6e , cells transfected with wild-type HRPAP20 exhibited significantly (Po0.01) increased invasion. In contrast, the level of invasion observed in the cells expressing the HRPAP20K73A variant did not differ from empty vector-transfected controls.
Other experiments were conducted to investigate whether an HRPAP20-CaM interaction was required for the increased MMP-9 activity observed. Here, the gelatinolytic activity present in conditioned medium obtained from empty vector-, wild-type HRPAP20-, or HRPAP20K73A-transfected MCF-7 cells was evaluated. As shown in Figure 7 , constitutive expression of wild-type HRPAP20 significantly increased MMP-9 secretion. However, disruption of HRPAP20-CaM association by transfection of the HRPAP20K73A variant decreased MMP-9 activity to a level that did not differ from empty vector controls. Together, these results suggest that association of HRPAP20 with CaM is important for increased MMP-9 secretion and the invasive phenotype afforded by elevated HRPAP20. 
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Discussion
Advances in molecular biology and genetics indicate that cancers progress toward increased malignancy by acquiring genetic mutations or aberrant expression of protein regulators that affect growth, survival and migration/invasion (Nakajima et al., 1987; Strobl et al., 1995; Sliva, 2004) . Previously, we showed that elevated HRPAP20 expression in rat lymphoma and human breast cancer cell lines increased proliferation and suppressed apoptosis (Karp et al., 2004) . As these observations were made in transfected cells, it was important to investigate the endogenous HRPAP20 levels present in breast cancer cell lines and patient tissue samples. We found that HRPAP20 levels were elevated in highly invasive breast cancer cells. Moreover, HRPAP20 levels in patient mammary specimens were significantly increased in tumors compared to the surrounding 'normal' breast epithelium and healthy tissue obtained from reduction mammoplasties. These observations suggest that HRPAP20 expression was increased as mammary cells progress toward a more malignant phenotype and that its level may reflect the stage of malignancy in breast tumors. We also report that constitutive expression of HRPAP20 in MCF-7 and MDA-MB-231 transfectants significantly increased the invasiveness of the cells. Notably, the inherent invasiveness of MDA-MB-231 cells was augmented by expression of HRPAP20, whereas its knockdown in wild-type cells reduced invasion. These observations suggest that HRPAP20 augmented invasion in human breast cancer cells, which may facilitate tumor metastasis.
An important characteristic associated with tumor progression is acquisition by cancer cells of the capacity to secrete and/or activate proteases, including MMPs (Reich et al., 1988; Garbett et al., 2000; Przybylowska et al., 2005) . Collectively, these enzymes are known to degrade a spectrum of ECM components including other pericellular proteins such as laminin, collagen and fibronectin (Nakajima et al., 1987) . Substrates of MMPs are not restricted to ECM proteins, but also include growth factor-binding proteins, their receptors, growth factor precursors and cell adhesion molecules (Miyazaki et al., 1994; Suzuki et al., 1997; Garbett et al., 2000) . MMP expression often correlates with a poor prognosis. To investigate potential mechanisms that may underlie the observed increase in invasive capacity provoked by elevated HRPAP20, we focused on MMP-9 as a candidate protease that degrades ECM proteins, reduces cancer cell apoptosis and increases angiogenesis, invasion and apoptosis (Ranuncolo et al., 2003; Stuelten et al., 2005) . Gelatin zymographic analysis of conditioned medium from MCF-7/HRPAP20 transfectants contained increased MMP-9 activity, suggesting that HRPAP20 leads to secretion of MMP-9. Moreover, MMP-9 secretion, exhibited by wild-type MDA-MB-231 cells, was significantly inhibited by knockdown of endogenous HRPAP20. These results are consistent with the hypothesis that HRPAP20 expression augmented invasion in breast cancer cells by a mechanism that involved increased secretion of MMP-9.
Motif scan analysis of HRPAP20, which revealed a putative CaM-binding sequence, was conducted to search for potential signaling mechanisms that may contribute to its observed biological actions. CaM has been shown to regulate a spectrum of cellular functions by activating enzymes such as mitogen-activated protein kinases (Enslen et al., 1996; Agell et al., 2002) and regulating mitogenic receptors such as the epidermal growth factor receptor (San Jose et al., 1992) . Thus, CaM-binding proteins play a central role in regulation of numerous cellular processes by serving as a link among signaling intermediates.
A possible interaction between the HRPAP20 and CaM was assessed by in vitro CaM-Sepharose pull-down analysis utilizing purified, recombinant HRPAP20-GST. HRPAP20-GST was found to complex with CaMSepharose, in the presence of Ca 2 þ , suggesting that a similar interaction may occur in cancer cells, which may contribute to the biological effects of HRPAP20. Co-immunoprecipitation/immunoblotting experiments conducted in MCF-7/HRPAP20 cells exhibited significantly elevated levels of co-immunoprecipitated CaM. Notably, previous studies indicated that alanine substitution of basic amino acids in the CaM-binding motif of myosin light-chain kinase and other CaM-binding proteins, abrogated CaM binding (Bagchi et al., 1992; Fitzsimons et al., 1992) . Therefore, an analogous basic residue, lysine 73, was identified within the putative CaM-binding domain of HRPAP20 and substituted with alanine. Consistent with previous observations, the loss of this charged residue reduced CaM binding to the HRPAP20K73A variant following its transfection into MCF-7 cells. To investigate whether the HRPAP20-CaM interaction affected tumor cell invasion, the invasive capacity of MCF-7 cells, transfected with either wild-type HRPAP20 or the K73A variant, were compared. In contrast to the wild-type protein, HRPAP20-K73A failed to enhance invasion. Therefore, it appeared that a physical association between HRPAP20 and CaM may be required for the increased invasion observed.
As increased MMP-9 secretion appeared to be regulated by HRPAP20, we compared the MMP-9 activity present in conditioned medium obtained from cells transfected with wild-type HRPAP20 or the HRPAP20K73A variant. The results indicated that secretion of MMP-9 was significantly reduced in cells expressing HRPAP20K73A implicating an upstream requirement for CaM binding for HRPAP20 to increase MMP-9 secretion.
Taken together, we conclude that HRPAP20 expression augmented invasiveness in human breast tumor cells by a mechanism that includes a protein-protein interaction with CaM, which led to increased MMP-9 secretion. Whether increased MMP-9 secretion was a direct effect of HRPAP20 gene expression warrants further investigation. The HRPAP20-CaM interaction provides additional clues to the mechanism by which HRPAP20 may regulate one or more signaling pathways involving CaM-dependent kinases or regulation of downstream gene targets. The presence of multiple potential regulatory motifs within HRPAP20 suggests that it may participate in several signaling pathways within tumor cells. Fully defining the role of HRPAP20 in breast cancer invasion may open new avenues for exploration of the mechanisms of tumor metastasis that may validate HRPAP20 as a new therapeutic target for breast cancer therapy.
Materials and methods
Cell culture MCF-7 and MDA-MB-231 cells were obtained from the American Type Culture Collection (Manassas, VA, USA). MDA-MB-435 cells were obtained from Dr Georg Weber (University of Cincinnati). Enzymatically active MMP-9 was obtained from Calbiochem (San Diego, CA, USA).
HRPAP20 transfection
The HRPAP20 cDNA was ligated into pcDNA 3.1 (Invitrogen, San Diego, CA, USA) and transfected into MCF-7 and MDA-MB-231 cells using TransFast (Promega Corp., Madison, WI, USA). Control cells were transfected with the empty vector. Stable transfectants were selected for neomycin resistance.
Site-directed mutagenesis
Site-directed mutagenesis of the CaM-binding domain of HRPAP20 was performed using the Quick-Change pointmutation kit (Stratagene, La Jolla, CA, USA). The expression vector, pcDNA 3.1 encoding wild-type HRPAP20, was used as a template. A forward primer encoding the site mutation at lysine 73 to alanine (K73A) was generated (5 0 -GAGATGT ATATGTCAATTCCGCAGATCCGGTGCCTTCCT-3 0 ). The reverse primer was complementary to the forward primer. A polymerase chain reaction (PCR) using the cycling conditions recommended by the manufacturer was conducted. Digestion of the parental template was accomplished using DpnI. The site mutant was transformed into Escherichia coli (DH5-a) and colonies selected on ampicillin-containing soft agar. Individual colonies were screened by DNA sequencing to confirm the site mutation.
HRPAP20 knockdown
Human and rat HRPAP20 (accession nos. NM_014165 and NM_198783, respectively) oligonucleotides were synthesized by Dharmacon Research Inc. (Lafayette, CO, USA) using SMARTpool technology. Non-targeting siRNA, bioinformatically designed to have X4 mismatches with known human and mouse genes, was used as a control. Cells were transfected with 10 nM of SMARTpool HRPAP20 siRNA or siCON-TROL using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA).
Real-time quantitative PCR Total RNA was isolated using RNAzol-B (Gibco, Carlsbad, CA, USA). Oligonucleotide primers and probes specific for HRPAP20 and b-actin or 18S mRNA were designed for use with TaqMan real-time PCR using Primer Express software (PE Applied Biosystems, Foster City, CA, USA). An ABI PRISM 7000 Sequence Detection System (Applied Biosystems, Foster City, CA, USA) was used to measure fluorescence during each PCR cycle. Data were analysed using a relative quantitation technique employing sequence detection systems software. Results were normalized to levels of b-actin or 18S mRNA present within samples.
Cell invasion assay
The invasive capacity of the breast tumor cell lines was measured utilizing an in vitro transwell assay (Repesh, 1989) . Cells, in Dulbecco's modified Eagle's medium (DMEM) containing 0.1% bovine serum albumin (BSA), were added to the upper well of transwell chambers (Corning Inc., Corning, NY, USA) containing an 8 mm porous membrane, previously coated with type I collagen, fibronectin and Matrigel (Becton Dickinson Biosciences, San Diego, CA, USA). Lower chambers contained 10% fetal bovine serum as a chemoattractant. Invading cells were fixed, stained with crystal violet and counted in five random fields/membrane.
Gelatin zymography
Conditioned medium obtained from 1 Â 10 4 cells was mixed with an equal volume of 2 Â sample buffer containing 0.5 M Tris (pH 6.8), 2% sodium dodecyl sulfate (SDS), 10% glycerol and 2.5% bromophenol blue; and loaded on 10% gels previously co-polymerized with 1 mg/ml of gelatin. SDSpolyacrylamide gel electrophoresis (SDS-PAGE) was followed by incubation of the gels in a renaturing buffer containing 2.5% Triton X-100 for 30 min at room temperature. The renaturing buffer was then replaced with developing buffer (50 mM Tris (pH 7.5), 0.2 M NaCl, 5 mM CaCl 2 , 0.02% Brij 35) and the gels were incubated for 16 h at 371C. Gels were then stained with Coomassie blue followed by destaining. Quantitation of clear bands of gelatin lysis was performed using densitometry. Purified, enzymatically active, MMP-9 was employed as a positive control.
Co-immunoprecipitation/immunoblotting MCF-7 cells, stably transfected with wild-type HRPAP20, HRPAP20K73A or the empty vector, were serum starved for 24 h in DMEM supplemented with 1% insulin-transferrinselenium (ITS) þ (BD Biosciences, Bedford, MA, USA) as a serum substitute, then lysed in a buffer containing 10 mM Tris (pH 7.4), 0.15 M NaCl, 5 mM ethylenediaminetetraacetic acid (EDTA) and 1% Triton X-100. The lysates were precleared with normal rabbit serum and protein G (Upstate, Lake Placid, NY, USA), then immunoprecipitated using a-HRPAP20 antiserum (Karp et al., 2004) and protein G. The immunoprecipitates, together with lysates, were resolved using 12% SDS-PAGE gels, then immunoblotted with a-CaM (Upstate, Charlottesville, VA, USA). The membranes were subsequently stripped using a buffer containing 62.5 mM Tris (pH 6.8) and 2% SDS, then reprobed with a-HRPAP20.
Recombinant HRPAP20-GST protein expression and purification Recombinant HRPAP20-GST protein was produced by transformation of the E. coli strain BL21 star/p-RARE with the plasmid vector PGEX-4T1 encoding for wild-type HRPAP20. The construct was sequenced at the University of Cincinnati's DNA Core Facility before transformation. Bacteria transformed with the empty vector alone were used to express recombinant GST used as an assay control. The transformants were grown in complete Luria-Bertani broth, and isopropyl b-D-thiogalactopyranoside (5 mM) was used to induce protein expression at 271C. Following 4 h of induction, the cells were lysed by freeze thawing (3 Â ) and sonication (60 V, five cycles). Sonicates were centrifuged and GST or HRPAP20-GST fusion proteins in the supernatants were purified using glutathione-agarose (Amersham, Piscataway, NJ, USA). Bound GST or HRPAP20-GST protein was eluted by reduced glutathione (20 mM) and quantitated using Bradford reagent (Bio-Rad, Hercules, CA, USA). The purity and molecular weights of the proteins were confirmed by SDS-PAGE followed by Coomassie blue staining.
CaM-Sepharose binding assay
Twenty microliters of CaM-Sepharose-4B beads (1.3 mg/ml, Amersham) were equilibriated with buffer A (150 mM NaCl, 50 mM Tris (pH 7.8), 1% Triton X-100, 1 mM EDTA75 mM CaCl 2 ) as described previously (Boehning et al., 2004 ). The equilibriated beads were then blocked for 1 h at room temperature with 1% BSA, followed by washing 1 Â with 500 ml of buffer A. Binding of HRPAP20-GST to CaM was evaluated by incubating 5 mg of HRPAP20-GST or GST-only with CaM-Sepharose beads for 1 h at 41C in buffer A in the presence or absence of CaCl 2 (5 mM). The beads were then washed 3 Â and bound protein was eluted using SDS sample buffer, followed by SDS-PAGE analysis. Immunoblotting with a-GST (sc-138, Santa Cruz Biotechnology, Santa Cruz, CA, USA) or a-HRPAP20 was used to identify HRPAP20 binding to CaM.
Statistical analysis
Data are presented as means7s.e.m. Statistical significance was evaluated by the Student's t-test (comparison of two mean values) or analysis of variance followed by the Student Newman-Keul's post-test for multiple comparisons. HRPAP20 mRNA levels in patient specimens were analysed using the Mann-Whitney U-test for comparison of two distinct data populations.
